Literature DB >> 9197300

Pharmacokinetics of rocuronium during the three stages of liver transplantation.

D M Fisher1, M A Ramsay, H A Hein, R J Marcel, M Sharma, K J Ramsay, R D Miller.   

Abstract

BACKGROUND: Little is known about the influence of liver transplantation on the pharmacokinetics of most anesthetic drugs. The authors determined the pharmacokinetics of rocuronium during liver transplantation and examined whether variability in pharmacokinetics could explain variability in recovery of neuromuscular function.
METHODS: Twenty patients undergoing liver transplantation were given rocuronium, 600 microg/kg, after induction of anesthesia and again after perfusion of the transplanted liver. Plasma was sampled to determine rocuronium concentrations. Pharmacokinetic models were fit to rocuronium concentrations versus time data using a mixed-effects population approach. Various models permitted changes in clearance (Cl) or central compartment volume to account for changes in hepatic function and circulatory status during the paleohepatic, anhepatic, and neohepatic periods. Time to initial recovery of four twitches of the orbicularis oculi was determined.
RESULTS: During the paleohepatic and anhepatic periods, the typical value of Cl was 2.47 ml x kg(-1) x min(-1) and was not influenced by the magnitude of preexisting liver disease (as evidenced by prothrombin time, bilirubin, serum albumin, alanine transaminase [ALT], and aspartate transaminase [AST]). During the neohepatic period, the typical value of Cl varied as a function of the duration of warm ischemia of the hepatic allograft and was 2.72 ml x kg(-1) x min(-1) for a patient with an average 60-min period of warm ischemia; time to neuromuscular recovery varied as a function of Cl.
CONCLUSIONS: Despite prolonged hypothermic ischemia, the newly transplanted liver eliminates rocuronium as well as the diseased native liver (and comparably with historical control values). However, some patients had decreased rocuronium Cl during the neohepatic period, apparently a result of prolonged graft warm ischemia. The authors' finding of preservation of hepatic drug elimination in the hepatic allograft is consistent with limited data for other drugs evaluated during anesthesia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9197300     DOI: 10.1097/00000542-199706000-00012

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  4 in total

Review 1.  Clinical pharmacokinetics of the newer neuromuscular blocking drugs.

Authors:  D P Atherton; J M Hunter
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

2.  Pharmacokinetic analysis of rapacuronium and its metabolite during liver transplantation: an assessment of its potential as a pharmacodynamic probe.

Authors:  Robert E Black; Ralph Gertler; Peter M C Wright; Mario T Cancemi; H A Tillmann Hein; Michael A E Ramsay
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-07

3.  Dose requirements of continuous infusion of rocuronium and atracurium throughout orthotopic liver transplantation in humans.

Authors:  Xiao-Chuan Weng; Liang Zhou; Yin-Yan Fu; Sheng-Mei Zhu; Hui-Liang He; Jian Wu
Journal:  J Zhejiang Univ Sci B       Date:  2005-09       Impact factor: 3.066

4.  Increased Renal Clearance of Rocuronium Compensates for Chronic Loss of Bile Excretion, via upregulation of Oatp2.

Authors:  Long Wang; Mai-Tao Zhou; Cai-Yang Chen; Wen Yin; Da-Xiang Wen; Chi-Wai Cheung; Li-Qun Yang; Wei-Feng Yu
Journal:  Sci Rep       Date:  2017-01-13       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.